Product Pipeline
Urological Diseases
Product
Target/Type
Region
Pre-Clinical
IND
Phase I
Phase II
Pivotal/Phase III
NDA
Vesique® (APL-1202)
MetAP2
Worldwide
China
NMIBC, intermediate/high risk, relapsed from chemotherapy (in combination with chemotherapy, second-line)
China
NMIBC, intermediate risk, untreated (single agent, first-line)
USA
NMIBC, intermediate/high risk, relapsed with BCG (in combination with BCG)
USA, China
Neoadjuvant therapy for MIBC (in combination with tislelizumab)
APL-1501
MetAP
Worldwide
Australia
Urological tumors; resistant UTI
Hexvix® (APL-1706)
Photosensitizer
China
NMIBC diagnosis and operation
Reproductive Diseases
Product
Target/Type
Region
Pre-Clinical
IND
Phase I
Phase II
Pivotal/Phase III
NDA
Cevira® (APL-1702)
Photodynamic drug-device combination product
Worldwide
International Multi-Center
Cervical high-grade squamous intraepithelial lesion (HSIL)
ASN-1764
Targeted protein degrader
Worldwide
Triple-negative breast cancer
ASN-1780
Targeted protein degrader
Worldwide
Metastatic castration-resistant prostate cancer
APL-1901
SERD
Worldwide
ER-positive breast cancer
Other Diseases
Product
Target/Type
Region
Pre-Clinical
IND
Phase I
Phase II
Pivotal/Phase III
NDA
APL-1401
DBH
Worldwide
Moderately to severely active ulcerative colitis
ASN-1733
Undisclosed
Worldwide
Acinetobacter baumannii infection
